Oak Harbor Wealth Partners LLC Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Oak Harbor Wealth Partners LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 0.8% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 71,453 shares of the biopharmaceutical company’s stock after purchasing an additional 549 shares during the quarter. Oak Harbor Wealth Partners LLC’s holdings in Pfizer were worth $1,999,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Ironvine Capital Partners LLC lifted its holdings in Pfizer by 2.1% in the 1st quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock worth $470,000 after purchasing an additional 353 shares in the last quarter. Patrick M Sweeney & Associates Inc. grew its position in shares of Pfizer by 0.8% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 42,162 shares of the biopharmaceutical company’s stock worth $1,180,000 after buying an additional 355 shares in the last quarter. Advisor OS LLC boosted its position in Pfizer by 1.0% during the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after purchasing an additional 365 shares in the last quarter. Lantz Financial LLC raised its stake in Pfizer by 1.3% in the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after buying an additional 381 shares during the last quarter. Finally, Wellington Shields Capital Management LLC raised its stake in Pfizer by 1.3% in the first quarter. Wellington Shields Capital Management LLC now owns 30,750 shares of the biopharmaceutical company’s stock valued at $853,000 after buying an additional 385 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on PFE shares. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays raised their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, BMO Capital Markets restated an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Trading Down 1.4 %

NYSE PFE traded down $0.41 on Friday, hitting $28.30. The company’s stock had a trading volume of 50,332,917 shares, compared to its average volume of 39,558,848. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $37.19. The company’s 50-day moving average is $28.75 and its 200 day moving average is $27.90. The firm has a market cap of $160.36 billion, a PE ratio of -471.59, a PEG ratio of 0.99 and a beta of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter last year, the firm earned $0.67 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, analysts predict that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.94%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.